{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:39:09Z","timestamp":1775241549548,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0161kolstv\u00ed, ml\u00e1de\u017ee a telov\u00fdchovy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00126","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T05:03:41Z","timestamp":1581051821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Jan","family":"Horak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Nalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vendula","family":"Martinkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaclav","family":"Tegl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Vistejnova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Kuncova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Kohoutova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Jarkovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Dolejsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Benes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Stengl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Matejovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7304121","DOI":"10.1155\/2017\/7304121","article-title":"Mesenchymal stem cells in sepsis and associated organ dysfunction: a promising future or blind alley?","volume":"2017","author":"Horak","year":"2017","journal-title":"Stem Cells Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e17850","DOI":"10.7554\/eLife.17850","article-title":"Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial","volume":"5","author":"Lalu","year":"2016","journal-title":"Elife."},{"key":"B3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/stem.2551","article-title":"Concise review: mesenchymal stem (stromal) cells: biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis","volume":"35","author":"Matthay","year":"2017","journal-title":"Stem Cells."},{"key":"B4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/SHK.0000000000001212","article-title":"Minimum quality threshold in pre-clinical sepsis studies (Mqtipss): an international expert consensus initiative for improvement of animal modeling in sepsis","volume":"50","author":"Osuchowski","year":"2018","journal-title":"Shock."},{"key":"B5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1164\/rccm.201705-1006OC","article-title":"Cellular immunotherapy for septic shock. A phase I clinical trial","volume":"197","author":"McIntyre","year":"2018","journal-title":"Am J Resp Crit Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/CCM.0000000000003657","article-title":"Effects of mesenchymal stem cell treatment on systemic cytokine levels in a phase 1 dose escalation safety trial of septic shock patients","volume":"47","author":"Schlosser","year":"2019","journal-title":"Crit Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40635-018-0194-1","article-title":"Clinical-grade mesenchymal stem cells derived from umbilical cord improve septic shock in pigs","volume":"6","author":"Laroye","year":"2018","journal-title":"Intensive Care Med Exp."},{"key":"B8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/CCM.0b013e3181cb0f61","article-title":"Reduced L-type calcium current in ventricular myocytes from pigs with hyperdynamic septic shock","volume":"38","author":"Stengl","year":"2010","journal-title":"Crit Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nm.1905","article-title":"Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production","volume":"15","author":"Nemeth","year":"2009","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1164\/rccm.201001-0010OC","article-title":"Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis","volume":"182","author":"Mei","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/thoraxjnl-2011-201176","article-title":"Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia","volume":"67","author":"Gupta","year":"2012","journal-title":"Thorax."},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/scrt385","article-title":"Apoptotic adipose-derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats","volume":"4","author":"Sung","year":"2013","journal-title":"Stem Cell Res Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/thoraxjnl-2015-206813","article-title":"Human mesenchymal stromal cells decrease the severity of acute lung injury","volume":"70","author":"Devaney","year":"2015","journal-title":"Thorax."},{"key":"B15","doi-asserted-by":"publisher","first-page":"L1003","DOI":"10.1152\/ajplung.00180.2011","article-title":"Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes","volume":"302","author":"Krasnodembskaya","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s00134-017-4821-1","article-title":"The intensive care medicine research agenda on septic shock","volume":"43","author":"Perner","year":"2017","journal-title":"Intensive Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ilar\/ilx007","article-title":"Murine models of sepsis and trauma: can we bridge the gap?","volume":"58","author":"Stortz","year":"2017","journal-title":"ILAR J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.shk.0000191337.01036.b7","article-title":"Porcine models of severe sepsis: emphasis on porcine peritonitis","volume":"24","author":"Goldfarb","year":"2005","journal-title":"Shock."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9399","DOI":"10.1038\/s41598-019-45871-z","article-title":"Conventional and specific-pathogen free rats respond differently to anesthesia and surgical trauma","volume":"9","author":"Letson","year":"2019","journal-title":"Sci Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jss.2016.12.008","article-title":"Vendor effects on murine gut microbiota influence experimental abdominal sepsis","volume":"211","author":"Hilbert","year":"2017","journal-title":"J Surg Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2019.02.038","article-title":"Specific pathogen-free (SPF) animal status as a variable in biomedical research: have we come full circle?","volume":"41","author":"Dobson","year":"2019","journal-title":"EBioMed."},{"key":"B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/prca.201470054","article-title":"Animal models for translational proteomics","volume":"8","author":"Bendixen","year":"2014","journal-title":"Prot Clin Appl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fimmu.2015.00560","article-title":"Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells","volume":"6","author":"Mattar","year":"2015","journal-title":"Front Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"6901286","DOI":"10.1155\/2016\/6901286","article-title":"Umbilical cord as prospective source for mesenchymal stem cell-based therapy","volume":"2016","author":"Arutyunyan","year":"2016","journal-title":"Stem Cells Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3892\/mmr.2016.5694","article-title":"Comparison of bone marrow tissue- and adipose tissue-derived mesenchymal stem cells in the treatment of sepsis in a murine model of lipopolysaccharide-induced sepsis","volume":"14","author":"Ou","year":"2016","journal-title":"Mol Med Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1182\/blood-2014-04-572255","article-title":"Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation","volume":"125","author":"Reinisch","year":"2015","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1002\/stem.2891","article-title":"Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single-blind, parallel group, placebo controlled trial","volume":"36","author":"Perlee","year":"2018","journal-title":"Stem Cells."},{"key":"B29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00109-019-01752-6","article-title":"Exploring the roles of MSCs in infections: focus on bacterial diseases","volume":"97","author":"Marrazzo","year":"2019","journal-title":"J Mol Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13287-015-0192-0","article-title":"Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis","volume":"6","author":"Alcayaga-Miranda","year":"2015","journal-title":"Stem Cell Res Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2016","journal-title":"Cytotherapy."},{"key":"B32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jcyt.2016.02.004","article-title":"A relativity concept in mesenchymal stromal cell manufacturing","volume":"18","author":"Martin","year":"2016","journal-title":"Cytotherapy."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","article-title":"Immunological characterization of multipotent mesenchymal stromal cells; The International Society for Cellular Therapy (ISCT) working proposal","volume":"15","author":"Krampera","year":"2013","journal-title":"Cytotherapy."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1097\/TXD.0000000000000724","article-title":"Influence of HLA matching on the efficacy of allogeneic mesenchymal stromal cell therapies for osteoarthritis and degenerative disc disease","volume":"3","author":"Garcia-Sancho","year":"2017","journal-title":"Transpl Dir."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1097\/TP.0000000000000678","article-title":"Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial","volume":"99","author":"Vega","year":"2015","journal-title":"Transplantation."},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","article-title":"Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial","volume":"3","author":"Wilson","year":"2015","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"E633","DOI":"10.3390\/cells8060633","article-title":"Pooling of patient-derived mesenchymal stromal cells reduces inter-individual confounder-associated variation without negative impact on cell viability, proliferation and osteogenic differentiation","volume":"8","author":"Widholz","year":"2019","journal-title":"Cells."},{"key":"B39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","article-title":"Sepsis: a roadmap for future research","volume":"15","author":"Cohen","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.stemcr.2016.05.001","article-title":"Setting global standards for stem cell research and clinical translation: The 2016 ISSCR Guidelines","volume":"6","author":"Daley","year":"2016","journal-title":"Stem Cell Rep."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T05:03:43Z","timestamp":1581051823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2020.00126"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00126","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"article-number":"126"}}